10x Genomics Past Earnings Performance

Past criteria checks 0/6

10x Genomics has been growing earnings at an average annual rate of 0.5%, while the Life Sciences industry saw earnings growing at 12.8% annually. Revenues have been growing at an average rate of 18.5% per year.

Key information

0.5%

Earnings growth rate

6.4%

EPS growth rate

Life Sciences Industry Growth36.9%
Revenue growth rate18.5%
Return on equity-25.7%
Net Margin-29.9%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How 10x Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0A88 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24611-183343264
30 Sep 24630-183331260
30 Jun 24632-240332261
31 Mar 24625-264337269
31 Dec 23619-255343266
30 Sep 23591-223331267
30 Jun 23568-172322268
31 Mar 23536-174312267
31 Dec 22516-166296264
30 Sep 22504-167289264
30 Jun 22498-142278251
31 Mar 22499-89267234
31 Dec 21490-58258212
30 Sep 21459-455244190
30 Jun 21406-504233165
31 Mar 21333-533209139
31 Dec 20299-543202123
30 Sep 20262-134185112
30 Jun 20251-78166104
31 Mar 20264-4915494
31 Dec 19246-3113183
30 Sep 19221-10011968
30 Jun 19197-10510557
31 Mar 19170-1059451
31 Dec 18146-1128848
31 Dec 1771-194732

Quality Earnings: 0A88 is currently unprofitable.

Growing Profit Margin: 0A88 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0A88 is unprofitable, but has reduced losses over the past 5 years at a rate of 0.5% per year.

Accelerating Growth: Unable to compare 0A88's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0A88 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (17.6%).


Return on Equity

High ROE: 0A88 has a negative Return on Equity (-25.72%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 10:39
End of Day Share Price 2025/02/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

10x Genomics, Inc. is covered by 21 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Luke SergottBarclays
Michael RyskinBofA Global Research